FDA backs Vytorin for kidney disease patients

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

The agency's online review also found no new safety concerns with Vytorin, which came under scrutiny for potential cancer risks in 2008.

Merck has asked the FDA to approve the drug for a new use in reducing heart-related problems patients. The combination pill is already cleared to reduce bad cholesterol.

FDA says that Vytorin lowered kidney disease patients' heart-related problems by 16 percent compared with placebo. However results varied depending on whether patients were receiving dialysis, standard treatment for patients with late-stage kidney disease who can no longer remove waste from their blood. Patients on dialysis only saw a six percent drop in heart problems, compared with a 22 percent reduction for healthier patients not on dialysis.

On Wednesday, the FDA will ask non-government advisers to comment on the disparity and to vote on the overall safety and efficacy of the drug for kidney disease patients.

Vytorin, a $2 billion-a-year drug for Merck, combines two brand-name cholesterol pills Zocor and Zetia.

In July 2008, preliminary results from a four-year study indicated a possible increased risk of cancer in patients getting Vytorin. But FDA's latest review found no evidence of a link between Vytorin and cancer.

"We believe these data should help lay to rest investor concerns about and Zetia's safety," Leerink Swann analyst Seamus Fernandez wrote in a research note Monday.

Shares of Merck & Co. Inc. fell 23 cents to $34.88 in morning trading Monday.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Heart drug 'safe for kidney patients'

Jun 13, 2011

(Medical Xpress) -- The full results of a trial show that people with chronic kidney disease can reduce their heart risk by taking a combination drug that lowers levels of ‘bad’ cholesterol.

Cholesterol drug shows benefits for kidney patients

Nov 22, 2010

(PhysOrg.com) -- A combination drug that lowers levels of 'bad' cholesterol in the blood can benefit people with chronic kidney disease and is safe, a study led by the Clinical Trial Service Unit at Oxford University has ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments